Asset Details
Do you wish to reserve the book?
Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic ex vivo perfusion
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic ex vivo perfusion
Do you wish to request the book?
Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic ex vivo perfusion
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic ex vivo perfusion
2024
Overview
Heart transplantation is associated with major hurdles, including the limited number of available organs for transplantation, the risk of rejection due to genetic discrepancies, and the burden of immunosuppression. In this study, we demonstrated the feasibility of permanent genetic engineering of the heart during ex vivo perfusion. Lentiviral vectors encoding for short hairpin RNAs targeting beta2-microglobulin (shβ2m) and class II transactivator (shCIITA) were delivered to the graft during two hours of normothermic EVHP. Highly efficient genetic engineering was indicated by stable reporter gene expression in endothelial cells and cardiomyocytes. Remarkably, swine leucocyte antigen (SLA) class I and SLA class II expression levels were decreased by 66% and 76%, respectively, in the vascular endothelium. Evaluation of lactate, troponin T, and LDH levels in the perfusate and histological analysis showed no additional cell injury or tissue damage caused by lentiviral vectors. Moreover, cytokine secretion profiles (IL-6, IL-8, and TNF-α) of non-transduced and lentiviral vector-transduced hearts were comparable. This study demonstrated the ex vivo generation of genetically engineered hearts without compromising tissue integrity. Downregulation of SLA expression may contribute to reduce the immunogenicity of the heart and support graft survival after allogeneic or xenogeneic transplantation.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antigens
/ beta 2-Microglobulin - genetics
/ Endothelial Cells - immunology
/ Endothelial Cells - metabolism
/ Enzymes
/ Heart Transplantation - methods
/ Histocompatibility Antigens Class I - genetics
/ Histocompatibility Antigens Class I - immunology
/ Histocompatibility Antigens Class I - metabolism
/ Histocompatibility Antigens Class II - genetics
/ Histocompatibility Antigens Class II - immunology
/ Histocompatibility Antigens Class II - metabolism
/ Hogs
/ Humans
/ Ischemia
/ Myocytes, Cardiac - immunology
/ Myocytes, Cardiac - metabolism
/ normothermic ex vivo perfusion
/ Plasmids
/ RNA, Small Interfering - genetics
/ Swine
/ Troponin
